Published in N Engl J Med on November 28, 1991
Engineering the proteolytic specificity of activated protein C improves its pharmacological properties. Proc Natl Acad Sci U S A (2003) 1.05
Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va. Protein Sci (1997) 1.04
Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo. J Thromb Haemost (2014) 0.95
Human protein C concentrate in the treatment of purpura fulminans: a retrospective analysis of safety and outcome in 94 pediatric patients. Crit Care (2010) 0.89
Proteolytic maturation of protein C upon engineering the mouse mammary gland to express furin. Proc Natl Acad Sci U S A (1995) 0.88
Models of the serine protease domain of the human antithrombotic plasma factor activated protein C and its zymogen. Protein Sci (1994) 0.84
Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C. J Clin Invest (1997) 0.83
Guidelines for the management of thrombophilia. Department of Haematology, The Royal London Hospital, Whitechapel, London, UK. Postgrad Med J (1996) 0.83
Protein C concentrate controls leukocyte recruitment during inflammation and improves survival during endotoxemia after efficient in vivo activation. Am J Pathol (2011) 0.82
Severe congenital protein C deficiency: the use of protein C concentrates (human) as replacement therapy for life-threatening blood-clotting complications. Biologics (2008) 0.82
Plasma antithrombin III and protein C levels in early recognition of late-onset sepsis in newborns. Eur J Pediatr (2006) 0.81
Protein C Thr315Ala variant results in gain of function but manifests as type II deficiency in diagnostic assays. Blood (2015) 0.77
Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis. Postgrad Med J (2003) 0.76
Use of human protein C concentrates in the treatment of patients with severe congenital protein C deficiency. Biologics (2010) 0.76
Pharmacokinetics of protein C and antithrombin in the fetal lamb: a model to predict human neonatal replacement dosing. Neonatology (2008) 0.75
The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia. Nat Genet (1999) 6.23
A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer (1981) 4.25
Occurrence of myeloproliferative disorder in patients with Noonan syndrome. J Pediatr (1997) 3.14
Myelodysplastic syndromes in childhood: report of 49 patients from a French multicentre study. French Society of Paediatric Haematology and Immunology. Br J Haematol (1996) 2.69
Antenatal glucocorticoid treatment and cystic periventricular leukomalacia in very premature infants. N Engl J Med (1999) 2.33
Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost (1992) 2.31
Deficiency of skeletal membrane protein band 4.1 in homozygous hereditary elliptocytosis. Implications for erythrocyte membrane stability. J Clin Invest (1981) 2.27
Blockade of CD40/CD40 ligand interactions prevents induction of factor VIII inhibitors in hemophilic mice but does not induce lasting immune tolerance. Thromb Haemost (2001) 2.16
Fetal platelet counts in thrombocytopenic pregnancy. Lancet (1990) 2.13
Antenatal thrombocytopenia in three patients with TAR (thrombocytopenia with absent radii) syndrome. Prenat Diagn (1993) 2.11
Mutations in ribosomal protein S19 gene and diamond blackfan anemia: wide variations in phenotypic expression. Blood (1999) 2.07
Plasma protein S deficiency in familial thrombotic disease. Blood (1984) 1.82
Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. J Clin Endocrinol Metab (2000) 1.78
Treatment of severe von Willebrand disease with a high-purity von Willebrand factor concentrate (Wilfactin): a prospective study of 50 patients. J Thromb Haemost (2007) 1.69
Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF: a tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP) Thromb Haemost (1999) 1.69
Relationship of plasma leucine and alpha-ketoisocaproate during a L-[1-13C]leucine infusion in man: a method for measuring human intracellular leucine tracer enrichment. Metabolism (1982) 1.65
Binding of disease-associated prion protein to plasminogen. Nature (2000) 1.64
The quality of life in adult female patients with congenital adrenal hyperplasia: a comprehensive study of the impact of genital malformations and chronic disease on female patients life. Eur J Pediatr (1995) 1.61
Fatal cerebral venous sinus thrombosis associated with the factor V Leiden mutation and the use of oral contraceptives. Thromb Haemost (1995) 1.59
Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost (1995) 1.58
Intravenous immunoglobulin therapy for prevention of infection in high-risk premature infants: report of a multicenter, double-blind study. Pediatrics (1991) 1.55
Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate. Arch Dermatol (1993) 1.55
Salivary cortisol levels throughout childhood and adolescence: relation with age, pubertal stage, and weight. Pediatr Res (1995) 1.54
Survival of very preterm infants: Epipage, a population based cohort study. Arch Dis Child Fetal Neonatal Ed (2004) 1.52
Species-dependent variability of ADAMTS13-mediated proteolysis of human recombinant von Willebrand factor. J Thromb Haemost (2009) 1.52
Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol (2000) 1.51
Repair of interrupted aortic arch: a ten-year experience. J Thorac Cardiovasc Surg (1996) 1.50
Long-term evaluation of the beneficial effect of subtotal splenectomy for management of hereditary spherocytosis. Blood (2001) 1.48
Restoration of normal membrane stability to unstable protein 4.1-deficient erythrocyte membranes by incorporation of purified protein 4.1. J Clin Invest (1986) 1.47
Truncus arteriosus repair: influence of techniques of right ventricular outflow tract reconstruction. J Thorac Cardiovasc Surg (1996) 1.46
Spurious monosomy 7 in leukemia due to centromeric heteromorphism. Cancer Genet Cytogenet (2000) 1.45
Mechanical ventilation in newborn infants with respiratory railure. Lancet (1968) 1.45
Growth hormone improves height in patients with juvenile idiopathic arthritis: 4-year data of a controlled study. J Pediatr (2003) 1.44
Activated protein C concentrate for the treatment of meningococcal endotoxin shock in rabbits. Shock (1998) 1.43
Transposition of the great arteries [S,D,L]. Pathologic anatomy, diagnosis, and surgical management of a newly recognized complex. J Thorac Cardiovasc Surg (1995) 1.43
[Maternofetal disseminated candidiasis and high-grade prematurity]. Arch Pediatr (1997) 1.42
Absent pulmonary valve syndrome: surgical treatment and considerations. Ann Thorac Surg (1996) 1.41
CYP21 mutations in simple virilizing congenital adrenal hyperplasia. J Mol Med (Berl) (2001) 1.39
Growth hormone deficiency in children with chromosomal abnormalities. Arch Dis Child (1990) 1.39
Intermittent microalbuminuria in children with type 1 diabetes mellitus without clinical evidence of nephropathy. Eur J Pediatr (1988) 1.39
Antenatal parvovirus infection: clinical implications. Pediatr Hematol Oncol (1998) 1.39
[The main principles of the decrees on perinatal care]. Arch Pediatr (1999) 1.37
[Cardiorespiratory arrest in full term newborn infants: six case reports]. Arch Pediatr (2004) 1.33
Safety requirement for use of inhaled nitric oxide in neonates. Lancet (1993) 1.33
Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes. Exp Clin Endocrinol Diabetes (2001) 1.32
Effect of whole-body x-ray irradiation on phospholipids of rat liver particulate fractions. Arch Biochem Biophys (1965) 1.31
Loss of attachment to fibronectin with terminal human erythroid differentiation. Blood (1990) 1.26
Immunochemical determination of cellular prion protein in plasma from healthy subjects and patients with sporadic CJD or other neurologic diseases. Transfusion (2001) 1.24
Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem (1995) 1.22
Red cell volume measurements and acute blood loss in high-risk newborn infants. J Pediatr (1977) 1.21
[Clinical and anatomo-pathologic study of 59 cases of sudden infant death]. Arch Fr Pediatr (1988) 1.20
Molecular basis of hereditary elliptocytosis due to protein 4.1 deficiency. N Engl J Med (1986) 1.19
Frequency of immune thrombocytopenia in newborns: a prospective study. Immune Thrombocytopenia Working Group. Blood (1997) 1.17
Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem (1995) 1.17
Surgical management of isolated multiple ventricular septal defects. Logical approach in 130 cases. J Thorac Cardiovasc Surg (1992) 1.16
Final height of patients with pituitary growth failure and changes in growth variables after long term hormonal therapy. Pediatr Res (1983) 1.16
A randomized, controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion (1998) 1.15
An isoform-specific mutation in the protein 4.1 gene results in hereditary elliptocytosis and complete deficiency of protein 4.1 in erythrocytes but not in nonerythroid cells. J Clin Invest (1993) 1.15
Prospective randomized multicenter comparison of high-frequency oscillatory ventilation and conventional ventilation in preterm infants of less than 30 weeks with respiratory distress syndrome. Pediatrics (2001) 1.13
Surgical treatment of subaortic stenosis: a seventeen-year experience. J Thorac Cardiovasc Surg (1999) 1.13
Population pharmacokinetics of midazolam in neonates. Clin Pharmacol Ther (1994) 1.13
The number of polymorphonuclear leukocytes in relation to gestational age in the newborn. Acta Paediatr Scand (1979) 1.13
Primary hematopoietic cells from DBA patients with mutations in RPL11 and RPS19 genes exhibit distinct erythroid phenotype in vitro. Cell Death Dis (2012) 1.12
Long-term fate of the coronary arteries after the arterial switch operation in newborns with transposition of the great arteries. Heart (1996) 1.12
Evidence for linkage of familial Diamond-Blackfan anemia to chromosome 8p23.3-p22 and for non-19q non-8p disease. Blood (2001) 1.12
Diamond-Blackfan anemia. Curr Opin Pediatr (2001) 1.11
Anatomic correction of transposition of the great arteries in neonates. J Am Coll Cardiol (1993) 1.11
Endorectal ultrasound: instrumentation and clinical aspects. Int J Colorectal Dis (1986) 1.10
Fatal post-splenectomy pneumococcal sepsis despite pneumococcal vaccine and penicillin prophylaxis. Lancet (1984) 1.09
Biventricular repair approach in ducto-dependent neonates with hypoplastic but morphologically normal left ventricle. J Am Coll Cardiol (1999) 1.09
Periventricular leukomalacia: risk factors revisited. Dev Med Child Neurol (1996) 1.08
Role of the Plasmodium falciparum mature-parasite-infected erythrocyte surface antigen (MESA/PfEMP-2) in malarial infection of erythrocytes. Blood (1995) 1.06
Molecular genetics and pathophysiology of 17 beta-hydroxysteroid dehydrogenase 3 deficiency. J Clin Endocrinol Metab (1996) 1.06
[Convulsions in the fifth day of life: a new syndrome?]. Arch Fr Pediatr (1977) 1.06
Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. J Thromb Haemost (2005) 1.06
Aortico-left ventricular tunnel in fetuses and infants. Ann Thorac Surg (1996) 1.06
Influence of routine administration of folic acid and iron during pregnancy. Gynecol Obstet Invest (1981) 1.05
Lineage- and stage-specific adhesion of human hematopoietic progenitor cells to extracellular matrices from marrow fibroblasts. Blood (1988) 1.05
Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. Br J Haematol (1985) 1.05
Anatomic correction of simple transposition of the great arteries in 50 neonates. Circulation (1987) 1.04
Glycophorin C content of human erythrocyte membrane is regulated by protein 4.1. Blood (1990) 1.04
Clinical, biochemical and molecular genetic data in five children with Gitelman's syndrome. Horm Metab Res (2001) 1.04
The alpha-keto acids of branched-chain amino acids: simplified derivatization for physiological samples and complete separation as quinoxalinols by packed column gas chromatography. Anal Biochem (1980) 1.03
Identification and quantitation of protein S in human platelets. Blood (1985) 1.02
Oral magnesium supplements reduce erythrocyte dehydration in patients with sickle cell disease. J Clin Invest (1997) 1.02
Temporal differences in membrane loss lead to distinct reticulocyte features in hereditary spherocytosis and in immune hemolytic anemia. Blood (2001) 1.02
Natural history of hereditary spherocytosis during the first year of life. Blood (2000) 1.01
Characterization of antibodies induced by human factor VIII in a murine knockout model of hemophilia A. Thromb Haemost (2000) 1.01
Unusual forms of tracheobronchial compression in infants with congenital heart disease. J Thorac Cardiovasc Surg (1996) 1.01
Diamond-Blackfan anaemia: genetic homogeneity for a gene on chromosome 19q13 restricted to 1.8 Mb. Nat Genet (1997) 1.01
Monitoring the bioavailability of FEIBA with a thrombin generation assay. J Thromb Haemost (2003) 1.00
[Proteinuria and loaiasis. Histologic, optic and electronic study of a case]. Bull Mem Soc Med Hop Paris (1967) 1.00
Human reticulocyte maturation and its relevance to erythropoietic stress. J Lab Clin Med (1979) 1.00
Red cell abnormalities in hereditary spherocytosis: relevance to diagnosis and understanding of the variable expression of clinical severity. J Lab Clin Med (1996) 1.00
[1st instance of the absence of an erythrocyte membrane protein (band 4(1)) in a case of familial elliptocytic anemia]. Nouv Rev Fr Hematol (1980) 1.00
Fetal and neonatal alloimmune thrombocytopenia: current trends in diagnosis and therapy. Transfus Med (1992) 0.99
Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation. J Clin Invest (1998) 0.99
Congenital mitral stenosis with or without associated defects: An evolving surgical strategy. Circulation (2000) 0.99